PsychoGenics Appoints Dr. Stephen Morairty as Vice President, Translational Neuroscience and Jean-Sebastien Valois as Vice President, Engineering and AI Development
PsychoGenics Inc. announced the appointment of Stephen Morairty, Ph.D., as Vice President of Translational Neuroscience and Jean-Sebastien Valois, MSc, as...
PsychoGenics Chief Innovation Officer Honored for Scientific Excellence
PsychoGenics announces that Daniela Brunner Ph.D., Chief Innovation Officer, was named the recipient of Great Minds in STEMTM (GMiS) Scientist of...
PsychoGenics Further Strengthens its Leadership Team, Adding Three Senior Executives
Daniela Brunner, Chief Innovation Officer; Geoffrey Varty, Executive Vice President, Research Operations; and Leslie Street, Vice President, Medicinal Chemistry PsychoGenics Inc....
PsychoGenics Drug Discovery Featured in Nature Biopharma Dealmakers
A phenotypic high-throughput approach to neuropsychiatric drug discovery Using its SmartCube platform along with machine learning algorithms, PsychoGenics has a...
Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration
Multi-year drug discovery collaboration leveraging behavioral and physiological phenotypic screening and machine learning to identify novel neuropsychiatric drug candidates Karuna...
PsychoGenics Awarded NIH HEAL Initiative Contract for Preclinical Screening Platform for Pain (PSPP)
PARAMUS, N.J., November 6, 2019 – PGI Holding Corporation (PsychoGenics) announced that it has been awarded an Indefinite Delivery Indefinite...
PsychoGenics Appoints Mark A. Varney, PhD as Chief Scientific Officer
PARAMUS, N.J., November 4, 2019 – PsychoGenics Inc., announced the appointment of Mark A. Varney, Ph.D., as Chief Scientific Officer...
Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia
September 27, 2019 – Marlborough, Mass., and Paramus, N.J. , – Sunovion Pharmaceuticals Inc. (Sunovion) and PsychoGenics Inc. (PsychoGenics), today...
Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia
May 10, 2019 – Marlborough, Mass., and Paramus, N.J., – Sunovion Pharmaceuticals Inc. (Sunovion) and PsychoGenics Inc. (PsychoGenics), today announced...